日本語AIでPubMedを検索
韓国でCOVID-19感染症の三次感染を引き起こした指標患者の症例：定量的RT-PCRでモニターしたCOVID-19感染肺炎の治療にロピナビル/リトナビルの適用を検討
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.
PMID: 32056407 PMCID: PMC7025910. DOI: 10.3346/jkms.2020.35.e79.
抄録
2019年12月中旬以降、中国・武漢からコロナウイルス病2019（COVID-19）感染が拡大している。韓国で確認されたCOVID-19患者は、中国から来た人、または中国を訪問した人です。二次感染が発生し、感染速度が加速していることから、集団感染への懸念が高まっています。54歳の男性は韓国で3人目のCOVID-19感染者と診断された。この患者は衣料品製造業の労働者で、入院当初は軽度の呼吸器症状と断続的な発熱を認め、入院6日目に胸部CTスキャンで肺炎症状を認めていた。この患者は二次感染1例，三次感染3例を引き起こした．本稿では，中国国外で初めて三次感染を起こした患者の臨床所見を報告する。興味深いことに，ロピナビル/リトナビル（Kaletra，AbbVie）投与後，β-コロナウイルスのウイルス負荷は有意に減少し，コロナウイルスの力価はゼロまたはほとんど認められなかった。
Since mid-December of 2019, coronavirus disease 2019 (COVID-19) infection has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 infection in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, β-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.
© 2020 The Korean Academy of Medical Sciences.